We use genomics and machine learning to detect residual solid tumor.

Residual Disease

Residual disease is cancer that remains after a treatment.

Patients with liquid tumors have benefited from a series of technical revolutions in residual disease detection. 

But patients with solid tumors like breast cancer have been left behind. Until now. 


About Us

We're a group of careful scientists, quietly working behind the scenes to arm those clinicians on the front lines of cancer care.


Culture of Innovation

Life-changing advances require an environment that nurtures unorthodox ideas while simultaneously rewarding methodical product development.

We strive to work along both ends of the innovation spectrum.

Supported by MBC Biolabs


Scientists, we need your help! Our team was selected by the NIH RADx initiative [1] to scale national COVID testing. Our project supports hospitals and clinical labs that run nucleic acid tests. Our mandate is to increase the number of SARS CoV-2 tests from ~0.5M per day to +5M per day by mid-September, before the influenza pandemic hits in the fall. This is an ambitious $30M+ public-private partnership with few historical precedents.

The first phase is a one-month project to optimize and validate the molecular assays. We need to submit our emergency authorization to FDA within one month so that manufacturers have time to scale production.

If you have laboratory experience with PCR and isothermal amplification assays, we need your help. We specifically need scientists with relevant graduate/postdoc or industry experience, and research associates highly skilled at PCR and isothermal amplification.

We’re recruiting a few scientists to start this week and a second wave to start next week. This will be a full-time effort for the next month. Our lab is located in San Carlos, CA [2].

Scientists from academia, industry and the government are taking leaves of absence to support this effort. Some plan to stay onboard as we advance to Phase 2, while others will return to their day jobs after we submit to FDA. If you want to help, but don’t know how to manage your current roles, reach out and we’ll find a way to make it work. Unprecedented challenges require an unprecedented scientific response.